Hemophilia

Dear Colleagues,

We invite medical professionals and researchers to submit articles for a special issue focused on the most recent developments in the field of hemophilia. This comprehensive collection aims to shed light on novel insights, cutting-edge treatments, and multidisciplinary approaches that enhance our understanding and management of this complex bleeding disorder.

Hemophilia, characterized by impaired blood clotting due to deficient or dysfunctional clotting factors, presents significant challenges to affected individuals and healthcare providers. This special issue serves as a platform to showcase innovative research spanning genetics, molecular mechanisms, diagnostics, and/or therapeutic approaches.

Contributors are encouraged to explore topics such as gene therapy breakthroughs, personalized treatment strategies, and the role of emerging technologies in addressing the underlying genetic causes.

We envision this special issue as a collaborative resource that not only highlights the progress made in hemophilia research, but also generates new ideas for future directions. By bringing together a diverse array of perspectives and expertise, we aim to facilitate a deeper understanding of hemophilia and ultimately improve the quality of life for those affected by this condition.

Dr. Eleni Gavriilaki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hemophilia A-B
• bleeding disorders
• coagulation disorders
• clotting factors
• hemostasis
• inherited bleeding disorders
• hemorrhage
• replacement therapy
• gene therapy for hemophilia
• hemophilia treatment centers
• hemarthrosis
• prophylactic treatment
• joint bleeds
• hemophilia genetics
• hemophilia carriers